IMV Inc.

Good day and thank you for standing by. Welcome to the IMV second quarter 2022 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will hear an automated message advising your hand is raised. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Brittany Davison, head of finance at IMV.

Thank you, operator, and good morning, everyone. I'm pleased to welcome you to IMV's second quarter 2022 clinical and operational update conference call. I'm joined today by Andrew Hall, our CEO, and Dr. Jeremy Graff, our chief scientific officer. During this call, we will discuss our business outlook and make forward-looking statements. Any forward-looking statements made today are pursuant to and within the meaning of safe harbor provisions of applicable securities laws. These comments are based on current expectations of management regarding future events and operating performance and should not be seen as guarantees of future performance or results. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks are discussed in our continuous disclosure documents filed in compliance with applicable securities law in Canada and the United States. The press release, MD&A, and financial statements have all been posted on our website at imv-inc.com. If you wish to receive a copy of these documents, please do not hesitate to contact us. Please note that we will only take questions from sell-side analysts. I will now turn the call over to Andrew to provide an overview of our recent highlights and progress. Andrew?

Thank you, Brittany, and welcome everyone to the IMV Q2 2022 operational update. I'll begin today's call with an overview of our business, our near-term clinical milestones and a refresh on our execution focus and strategic plan to ensure cash optimisation. Jeremy will then provide additional colour on our clinical programs and Brittany will provide an overview of the financial results for the second quarter ended June 30. I will then wrap up before we take questions. I would like to begin the call by restating our strategic priorities as these inform near-term significant value creating milestones. We are accelerating Maverick Peppermint towards registration trials by completing Phase 2B clinical proof-of-concept studies that will validate A, that the DPX delivery platform uniquely makes vaccines in oncology viable, and B, that Maverick Peppermint S has a de-risk path to registration in DLBCL and ovarian cancer. We have already demonstrated clinical benefit in DLBCL, ovarian, and metastatic bladder cancer with maverick peppermint S. These promising results now require the robustness of a company-sponsored, FDA-endorsed, multi-centered Phase IIb study. In quarter three of this year, we will provide the first insight into these data with an early look at the vitalized study in DLBCL. In the first half of next year, we expect to complete enrolment of the first stage of this study, and then six months following, we will also complete enrolment of the first stage of our Phase 2b ovarian cancer trial, Avalon. In summary, in the next 12 months, we will complete enrolment and provide preliminary data of the first stage of two Phase 2b FDA-endorsed, multi-centred, company-sponsored trials. Strategic priority number two is the DPX platform. We are investing in the scientific foundation of IMV, the DPX technology to drive platform-based business development opportunities. The IMV research focus is to confirm that DPX technologies overcome many of the drivers of previous failures in the area of immune oncology. In a moment, Jeremy will give more details about the capability of our technology platform compared to other cancer vaccines and how the first results of our clinical trials should validate the broad applicability of DPX and create excitement about our delivery platform amongst the industry. Executing on our clinical and BD milestones in the context of the current market conditions is the right two-pronged strategy. We recognise that we have a finite amount of capital resources and are prudently allocating capital to those opportunities that have the greatest value-creating potential. At the same time, we have been carefully eliminating non-strategic spend. Having initiated enrolment in the Vitalise trial earlier this year, we now have sites in the EU, North America, New Zealand and Australia. These additional sites have bolstered the pace of enrolment and we remain on track to give the first results on early patients in the third quarter of this year. We will also plan to complete enrolment of Stage 1 in the first half of 2023. Regarding Avalon, our Phase 2b trial for women with platinum resistant ovarian cancer I am pleased to announce today that we have dosed our first patient and we are targeting enrollment completion of stage one in the summer of 2023. Based on the data presented at AACR in April, and discussions we've had with thought leadership, we believe there is also a compelling opportunity for Maverick Peppermint in patients with advanced metastatic bladder cancer. However, for financial prudence, we will not pursue a bladder program alone and are seeking partners who have expertise in this space to advance the program whilst delivering the right economics to IMV. Finally, Our clinical study in non-muscle invasive bladder cancer in evaluating maverick peppermint and the dual targeted DPX-SumAge continues to progress rapidly through recruitment. This study aims to confirm the versatility of our platform to safely deliver multiple targets in a durable and effective way. A feature of DPX that is extremely informative to business development conversations we are having. We expect to have preliminary results from this study by the end of the year with the maverick peppermint arm and in the first half of 2023 with the DPXMH. Now, I'm turning the call over to Jeremy to provide an overview of our scientific and clinical programs. Jeremy?